Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Glucose hypometabolism and gray matter atrophy are well known consequences of
Alzheimer's disease (AD). Studies using these measures have shown that the earliest …

Background Mild cognitive impairment (MCI) is a well-recognised risk factor for dementia
and represents a vital opportunity for intervening. Exercise is a promising strategy for …

Diffusion imaging can assess the white matter connections within the brain, revealing how
neural pathways break down in Alzheimer's disease (AD). We analyzed 3‐Tesla whole …

Objectives We have described cerebrospinal fluid (CSF) myeloid microvesicles (MVs) as a
marker of microglia activation during neuroinflammation in Alzheimer disease (AD), and …

Structures of the medial temporal lobe (MTL) are known to be involved in declarative
memory processes. However, little is known about how age‐related changes in MTL …

Current treatments for Alzheimer's disease are only symptomatic and limited to reduce the
progression rate of the mental deterioration. Mild Cognitive Impairment, a transitional stage …

The posteromedial cortex (PMC) and medial temporal lobes (MTL) are two brain regions
particularly vulnerable in Alzheimer's disease (AD). We have reviewed the spatiotemporal …

While mild cognitive impairment (MCI) has been classified into amnestic MCI (aMCI) and
nonamnestic MCI (naMCI), the neuropathological bases of these two subtypes remain …

Although much prior work has focused on the known cortical pathology that defines
Alzheimer's disease (AD) histologically, recent work has additionally demonstrated …